ERBB2 and neoplasm: HER2’s oncogenic activity confers a strong proliferative advantage to tumor cells, which includes increased tumor size, lymph node invasion, aneuploidy, percentage of cells in S-phase, and tumor grade resulting in an overall increased aggressiveness of the tumor (35–37).